|
Match
|
Document |
Document Title |
|
|
7368542 |
Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter...
|
|
|
7288254 |
Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and...
|
|
|
7241592 |
Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use
Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross...
|
|
|
7186410 |
Method for preparing human immunoglobulin concentrates for therapeutic use
The invention concerns a method for preparing human immunoglobulin concentrates for therapeutic use, from plasma or a plasma fraction. The method comprises pre-purification and a single...
|
|
|
7138120 |
Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
The present invention relates to a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. Said process includes a number of steps of which the anion...
|
|
|
7125552 |
Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin...
|
|
|
7041798 |
Method for the chromatographic fractionation of plasma or serum, preparations, so obtained, and their use
The invention relates to the fractionation of plasma or serum into at least one albumin fraction and one immunoglobulin fraction by hydrophobic interaction chromatography. The fractionation is...
|
|
|
7014847 |
Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders,...
|
|
|
6893639 |
Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin...
|
|
|
6875848 |
Process for the production of virus-inactivated human gammaglobulin G
The gammaglobulin is extracted from a fraction isolated by fractionation with ethanol in the presence of a carbohydrate, and after reducing the content of contaminants with PEG, it is applied to an...
|
|
|
6875432 |
Reduced-viscosity concentrated protein formulations
The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method...
|
|
|
6869605 |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
|
|
|
6849259 |
Polyclonal antibody composition for treating allergy
A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies...
|
|
|
6709655 |
Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
The present invention is directed to a pharmaceutical composition comprising F(ab′) 2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free...
|
|
|
6686191 |
Preparation of virally inactivated intravenously injectable immune serum globulin
Method of reducing the anticomplement activity (ACA) resulting from viral inactivation treatment of a solution of antibodies, the method comprising contacting the solution with a trialkylphosphate,...
|
|
|
6646108 |
Process for isolating IgG and IgA
A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a...
|
|
|
6485932 |
Composition comprising immunoglobulin
Liquid compositions for intravenous administration that comprise an aqueous solution of immunoglobulin and methods of preparing such compositions are disclosed. The solution has a pH in the range...
|
|
|
6485725 |
Room temperature storable immunoglobulin preparation for intravenous injection
A method for producing an immunoglobulin preparation for intravenous injection, which comprises the steps of: fractionating an immunoglobulin-containing solution with 4 to 10 w/v% of polyethylene...
|
|
|
6281336 |
Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
The present invention relates to a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. Said process includes a number of steps of which the anion...
|
|
|
6252055 |
Concentrated antibody preparation
Concentrated monoclonal antibody preparations for administration to humans are described in which the antibody is present at a concentration of greater than 100 mg/ml and as high as 350 mg/ml.
|
|
|
6238664 |
Process for stabilizing proteins
An aqueous protein solution buffered with a potassium phosphate buffer, in which the ratio of potassium ions to sodium ions in the solution is at least 10:1, is resistant to the formation of...
|
|
|
6165467 |
Stabilized human monoclonal antibody preparation
A stabilized human monoclonal antibody preparation containing 1 to 20 mg of D-mannitol per 1 mg of a human monoclonal antibody. This preparation is excellent in stability in a solution state, a...
|
|
|
6136312 |
Method for producing an IgM preparation for intravenous application
In the method for producing an immunoglobulin solution suitable for intravenous application with an IgM proportion of more than 5% by weight with respect to the immunoglobulin proportion, an...
|
|
|
6090380 |
Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
Pooled human immunoglobulin may be administered orally to rheumatoid arthritis patients to treat the rheumatoid arthritic condition of those patients. Oral administration of pooled human...
|
|
|
5972632 |
Anticomplement activity assays
Immunoassays for complement components, complement activation products or, preferably both, can be used to determine an acceptable level of anticomplement activity (AC) in plasma derived...
|
|
|
5871950 |
Methods of treating autoimmune diseases and transplantation rejection
The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment...
|
|
|
5871736 |
Liquid immunoglobulin formulations
Immunoglobulin preparations, particularly liquid preparations of immunogllin G for intravenous infusion, are stabilized against dimer formation by the addition of one or more amphiphilic...
|
|
|
5612033 |
Methods of treatment using heat-treated IGM antibody preparations
Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM...
|
|
|
5510465 |
Heat-treated IgM antibody preparations
Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM...
|
|
|
5447722 |
Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals
A method for suppressing the capacity of a mammal to mount an immune response which would be caused by the administration of one or more biologically active foreign proteins, comprising the...
|
|
|
5256771 |
Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM...
|
|
|
5234685 |
Method of determining incompatibility-reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances
There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating...
|
|
|
5190752 |
Intravenously administerable polyclonal immunoglobulin preparation containing IgM and method of manufacture
An intravenously administrable polyclonal immunoglobulin preparation for the treatment and prophylaxis of bacterial infections containing at least 50% by weight of IgM in terms of the total content...
|
|
|
5177194 |
Process for purifying immune serum globulins
A multi-step process for purifying an immune serum globulin fraction from a crude plasma protein fraction involves precipitating non-serum globulin proteins from an aqueous suspension of the crude...
|
|
|
5132406 |
Method of producing immunoglobulin preparations for intravenous injection
A method of producing immunoglobulin preparations for intravenous injection which starts with an immunoblobulin-containing fraction and comprises the treatment steps of: (a) treating said...
|
|
|
5122373 |
Immunoglobulin-G-containing fraction
An immunoglobulin-G-containing fraction from human or animal plasma comprising monomeric IgG molecules as well as at least 70% gammaglobulins, destined for intravenous application. The fraction has...
|
|
|
5087695 |
Immunoglobulin extraction utilizing properties of colloidal solutions
An immunoglobulin-rich fraction containing IgG, IgA and IgM is prepared in high concentration (200 mg/ml) by contacting diluted serum with CuSO 4 , which is a source of strong positive ions, to...
|
|
|
5075425 |
Process for the preparation of a pharmaceutical which contains IgG, IgA and IgM and can be administered intravenously
Process for the preparation of an immunoglobulin solution suitable for intravenous administration from a human blood protein fraction containing immunoglobulins IgG, IgA and IgM in partially...
|
|
|
4965068 |
Polyvalent hyperimmunoglobulin preparation
The present invention involves a polyvalent hyperimmunoglobulin preparation having activity against gram negative and gram positive bacteria. Such a polyvalent hyperimmunoglobulin preparation is...
|
|
|
4902500 |
Stabilization of antibodies
According to the present invention antibody preparations are more stable during storage if in addition they contain a mixture of at least one polyoxypropylene-polyoxyethylene block polymer (such as...
|
|
|
4880913 |
Process for the preparation of an immunoglobulin which can be administered intravenously and is stable in liquid form
The invention relates to a process for the preparation of an immunoglobulin which has no side effects, is stable on storage in liquid form and can be administered intravenously and which has a...
|
|
|
4877866 |
Method of producing a virus safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation
A method of producing a virus-safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation. The object is to make the method appropriate for industrial-scale production and...
|
|
|
4877608 |
Pharmaceutical plasma protein formulations in low ionic strength media
Stable factor VIII and other plasma protein formulations are provided in low ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; lysine hydrochloride; and...
|
|
|
4876088 |
Gamma-globulin injectable solutions containing sorbitol
An intravenously injectable solution of chemically unmodified γ-globulin having a complete molecular structure is disclosed, said solution containing sorbitol as a stabilizer and having a low...
|
|
|
4874708 |
Process for the preparation of intra-venously administered gamma-globulins and the gamma-globulins obtained
A solution of gamma-globulins, coming for example from Cohn's fractionation, is submitted to a step of fractionation with polyethylene-glycol, a step of moderated enzymatic treatment with pepsin,...
|
|
|
4849508 |
Pasteurization of immunoglobulin solutions
Pasteurization of immunoglobulin solutions to inactivate viruses without significantly altering the IgG molecules or their physiological activities is obtained with minimal aggregation in the...
|
|
|
4845199 |
Process for heat treating chemically unmodified gamma-globulin
A process for heat treating an aqueous solution containing chemically unmodified γ-globulin, wherein said heat treating is carried out in the presence of sorbitol is disclosed. By the heat...
|
|
|
4835257 |
Process for preparing gamma globulin suitable for intravenous administration using peg and a citrate buffer
An improved process for the preparation of gamma globulin suitable for intravenous administration comprises dissolving gamma globulin precipitated from blood or blood products in a solution,...
|
|
|
4801450 |
High titer pseudomonas immune serum globulin
Normal plasma from donors who have not been vaccinated with a P seudomonas vaccine or had a Pseudomonas infection can be screened for higher than normal titers of naturally occurring antibody to...
|
|
|
4800078 |
Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
A new immunotherapeutic method of treating lower respiratory tract infection caused by respiratory syncytial virus (RSV) is disclosed. The method employs topical application of RSV antibodies into...
|